Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: A randomised, double-blind phase 1/2a clinical trial

The Lancet Infectious Diseases

Volumn 14, Issue 12, 2014, Pages 1196-1207

  Kreijtz, Joost H C M ^a   Goeijenbier, Marco ^a   Moesker, Fleur M ^a   van den Dries, Lennert ^a   Goeijenbier, Simone ^a   De Gruyter, Heidi L M ^a   Lehmann, Michael H ^b,c   de Mutsert, Gerrie ^a   van de Vijver, David A M C ^a   Volz, Asisa ^b,c   Fouchier, Ron A M ^a   van Gorp, Eric C M ^a   Rimmelzwaan, Guus F ^a   Sutter, Gerd ^b,c   Osterhaus, Albert D M E ^a,d,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MUNICH   (Germany)

^c German Center for Infection Research   (Germany)

^d Research Institute for Wildlife Health in Europe   (Netherlands)

^e UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; MODIFIED VACCINIA VIRUS ANKARA BASED INFLUENZA A H5N1 VACCINE; UNCLASSIFIED DRUG; DRUG CARRIER; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA NODOSUM; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN REDNESS; SORE THROAT; SWELLING; VACCINIA VIRUS; ADOLESCENT; ANIMAL; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE VECTOR; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC VECTORS; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; VACCINES, SYNTHETIC; VACCINIA VIRUS; YOUNG ADULT;

EID: 84921462712     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70963-6     Document Type: Article

References (35)

1. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL A pandemic warning?. Nature 1997, 389:554.
2. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO WHO, (accessed June 5, 2014). http://www.who.int/influenza/human_animal_interface/EN_GIP_20140124CumulativeNumberH5N1cases.pdf.
3. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application EMA, (accessed June 5, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003869.pdf.
4. Collin N, de Radigues X Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009, 27:5184-5186. World Health Organization HNVTF.
5. Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009 WHO, (accessed June 5, 2014). http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10-en.pdf.
6. Couch RB, Decker WK, Utama B, et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One 2012, 7:e50830.
7. Clegg CH, Rininger JA, Baldwin SL Clinical vaccine development for H5N1 influenza. Expert Rev Vaccines 2013, 12:767-777.
8. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K H5N1 vaccines in humans. Virus Res 2013, 178:78-98.
9. Luke CJ, Subbarao K Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev Vaccines 2014, 13:873-883.
10. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin 2009, 5:126-135.
11. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness WHO, (accessed June 5, 2014). http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf.
12. Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 2013, 20:85-94.
13. Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013, 13:238-250.
14. Peters W, Brandl JR, Lindbloom JD, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013, 31:1752-1758.
15. Kreijtz JH, Suezer Y, de Mutsert G, et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 2009, 4:e7790.
16. Kreijtz JH, Suezer Y, de Mutsert G, et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009, 199:405-413.
17. Kreijtz JH, Suezer Y, van Amerongen G, et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007, 195:1598-1606.
18. Veits J, Romer-Oberdorfer A, Helferich D, et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008, 26:1688-1696.
19. Hessel A, Savidis-Dacho H, Coulibaly S, et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One 2014, 9:e88340.
20. Hessel A, Schwendinger M, Holzer GW, et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 2011, 6:e16247.
21. Protocol MVA-H5 clinical trial ViroscienceLab, (accessed June 25, 2014). http://virosciencelab.org/wp-content/uploads/2013/01/Protocol-MVA-H5-clinical-trial.pdf.
22. Palmer D, Dowle W, Coleman M, Schild G Haemagglutination inhibition test. Immunology series number 6. Advanced laboratory techniques for influenza diagnosis. Procedural guide 1975, 25-62. US Department of Health, Atlanta.
23. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010, 50:1487-1492.
24. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336:1534-1541.
25. Linster M, van Boheemen S, de Graaf M, et al. Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus. Cell 2014, 157:329-339.
26. Gilbert SC Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 2013, 31:4241-4246.
27. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009, 106:7962-7967.
28. Cottingham MG, Carroll MW Recombinant MVA vaccines: dispelling the myths. Vaccine 2013, 31:4247-4251.
29. Stittelaar KJ, Wyatt LS, de Swart RL, et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 2000, 74:4236-4243.
30. Moss B Smallpox vaccines: targets of protective immunity. Immunol Rev 2011, 239:8-26.
31. Baur K, Brinkmann K, Schweneker M, et al. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol 2010, 84:8743-8752.
32. Powell TJ, Peng Y, Berthoud TK, et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One 2013, 8:e62778.
33. Antrobus RD, Lillie PJ, Berthoud TK, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012, 7:e48322.
34. Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55:19-25.
35. Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.